β1 Adrenergic Receptor Polymorphisms and Heart Failure: A Meta-Analysis on Susceptibility, Response to β-Blocker Therapy and Prognosis

Wen-Nan Liu1,2,9, Kai-Li Fu1,2,9, Hai-Yang Gao1,2, Yuan-Yuan Shang1,2, Zhi-Hao Wang1,2, Gui-Hua Jiang1,2, Yun Zhang1,2, Wei Zhang1,2, Ming Zhong1,2*

1 Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Jinan, People’s Republic of China, 2 Department of Cardiology, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

Abstract

Aims: The risk stratification of patients for heart failure (HF) remains a challenge, as well as the anticipation of the response to β-blocker therapy. Since the pivotal role of β1 adrenergic receptor (β1-AR) in HF, many publications have studied the associations between the β1-AR polymorphisms (Ser49Gly and Arg389Gly) and HF, with inconsistent results. Thus, we performed a meta-analysis of studies to evaluate the impact of β1-AR polymorphisms on susceptibility to HF, the response to β-blocker therapy and the prognosis of HF.

Methods and Results: Electronic databases were systematically searched before August 2011. We extracted data sets and performed meta-analysis with standardized methods. A total of 27 studies met our inclusion criteria. It was found that in East Asians, the Gly389 allele and Gly389 homozygotes significantly increased the HF risk, while the Gly389 allele and Gly389 homozygotes trended to decrease the risk of HF in whites. With the similar reduction of heart rate, overall, the Arg389 homozygotes showed a better response to β-blocker therapy. Furthermore, the Arg389 homozygotes were significantly associated with better LVEF improvement in East Asians and a mixed population. And in white people, the Arg389 homozygotes made a greater LVEF improvement and trended to be associated with better LVESd/v improvement. However, the prognosis of Arg389 homozygote HF patients was similar to those with Gly389 carriers.

Conclusion: Based on our meta-analysis, the Gly389 allele and Gly389 homozygotes were risk factors in East Asians while trend to protect whites against HF. Furthermore, Arg389 homozygote is significantly associated with a favorable response to β-blocker treatment in HF patients. However, neither of the two polymorphisms is an independent predictor of the prognosis of HF.

Introduction

Heart failure (HF) is the end-stage of various heart diseases, and it represents a major health problem owing to its high prevalence, morbidity, mortality and significant health-care costs [1–2]. β-blockers are mainstay of current treatment of heart failure (HF) in guideline, for their administration has beneficial effects on left ventricular (LV) function and prognosis [1–7]. However, in clinical practice, the response to β-blocker therapy and prognosis of HF are variable among patients. The purpose of diagnosing and treating HF is bringing about a reduction of mortality and morbidity. It is therefore important to identify the risk factors for HF so that preventive measurements can be undertaken early; and anticipation the response to β-blockers would help the physicians to make therapeutic decision. Thus there are needs for risk stratification tools of HF and predictors of response to β-blockers treatment, which are still challenges in the real world.

As the targets of endogenous catecholamines and β-blockers, β1 adrenergic receptor is known to play a pivotal role in the progression and treatment of HF [8]. Two common functional polymorphisms of the β1-AR, Ser49Gly and Arg389Gly have been considered as predictors of susceptibility to HF, response to β-blockers therapy and even prognosis of HF in some publications. However, being limited by small sample size, the results are controversial. Thus, we performed this meta-analysis of all the available studies to evaluate the impacts of β1 AR polymorphisms on susceptibility to HF, response to β-blocker therapy, and
prognosis. It may provide information for further investigation on individualized HF prevention and treatment.

**Methods**

**Search and Selection Process**

Electronic searches by PubMed, Cochrane Library, and Chinese Biomedical Disc were used to identify published articles on β1 AR polymorphisms and heart failure. We combined search terms for “β1 receptor genetic polymorphism”, “ADRB1 polymorphism”, “Ser49Gly”, “Arg389Gly”, and all of the studies were published before August 2011. When more than one of the same patient population was included in several publications, only the most recent or complete study was identified in this meta-analysis.

**Inclusion Criteria**

For the susceptibility to heart failure: (1) case-control studies, (2) evaluating the association between the β1 adrenergic receptor genetic polymorphisms and HF risk, (3) the diagnosis of HF was made according to the World Health Organization criteria, based on the presence of the typical clinical signs and symptoms of HF with left ventricular dysfunction.

Response to β-blockers therapy: (1) The definition of HF was based on the World Health Organization criteria, (2) evaluation of β1 AR genetic polymorphisms on the reduction of heart rate (ΔHR), the changes of left ventricular ejection fraction (ΔLVEF), left ventricular end-diastolic diameter/volume (ΔLVEDd/v), left ventricular end-systolic diameter/volume (ΔLVESd/v), with at least 3 months follow up, (3) all the patients received β-blockers therapy, other medicines such as ACEI/ARB, diuretics, spironolactone, and digoxin were used when necessary.

β1 AR polymorphisms and HF prognosis: (1) The definition of HF was based on the World Health Organization criteria, (2) evaluation of β1 adrenergic receptor genetic polymorphisms on all-cause mortality or combined end-point including death, heart transplantation and hospitalization, (3) patients were followed up for more than 1 year.

All the searches were restricted to articles in English or Chinese. Case reports, editorials, and review articles were excluded.

**Data Extraction**

Two reviewers independently extracted data from published sources. The following information was extracted from each study: the first author, publication year, study design, ethnicity, sample size, distribution of genotypes, Hardy-Weinberg equilibrium (HWE) in controls, the parameters of therapy response (ΔHR, ΔLVEF, ΔLVEDd/v, and ΔLVESd/v), and the occurrence of death and combined end-point. We did not define any minimum number of subjects as required to include a study in our meta-analysis. If necessary data could not be extracted, the study authors were contacted by e-mail, with a reminder after 30 days. Disagreements were resolved by joint review and consensus.

**Statistics**

Cochrane collaboration meta-analysis review methodology was used for this study [9]. The allele contrast, the recessive and dominant models were evaluated for association between the risk of heart failure and the β1 AR polymorphisms. In addition to the overall analysis, subgroup analysis for each ethnicity was also performed. Ethnicity was categorized into 3 main groups: (1) white descents, (2) East Asian descents, and (3) black descents. The distribution of the genotypes in the control group was tested for Hardy–Weinberg equilibrium [9], a P<0.05 was considered that the distribution of genotypes in the control group deviated from HWE. Studies with controls not in HWE were subjected to a sensitivity analysis.

In the meta-analysis of influence on HF patients therapy response and prognosis, comparisons of therapy response parameters (ΔHR, ΔLVEF, ΔLVEDd/v, ΔLVESd/v) and prognosis (mortality and combined end-point) between Gly49 carriers (Gly49Gly + Ser49Gly) and Ser49 homozygotes, Gly389 carriers (Gly389Gly + Arg389Gly) and Arg389 homozygotes were carried out respectively.

The analysis was carried out using Review Manager statistical software (RevMan version 5.0.2; The Nordic Cochrane Center, Regshospitalet). Pooled relative risk (RR) and associated 95% confidence intervals (CIs) were calculated for the risk and prognosis of HF. The therapy response was evaluated with weighted mean difference (WMD) for ΔHR and ΔLVEF, or standardized mean difference (SMD) for ΔLVEDd/LVEDv, ΔLVESd/LVESv. All tests and CIs were 2-sided, and a P<0.05 was considered statistically significant.

The presence of heterogeneity across studies was evaluated. The fixed-model (Mantel–Haenszel) was used when smaller heterogeneity was available (P<0.1), otherwise the random model (DerSimonian and Laird) was used [11]. Heterogeneity was assessed with I2 test, which described the proportion of variation in the log RR that is attributable to genuine differences across studies rather than to random error. I2 took values between 0% and 100% with higher values denoting greater degree of heterogeneity (I2 = 0% to 25%: no heterogeneity; I2 = 25% to 50%: moderate heterogeneity; I2 = 50% to 75%: large heterogeneity; I2 = 75% to 100%: extreme heterogeneity). Publication bias was assessed using a funnel plot of effect size against standard error.

**Results**

**Eligible Studies**

A total of 345 potentially eligible studies were identified, of which 291 were excluded after reviewing the study abstracts. The retrieved studies were then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. As shown in Table 1, fourteen studies were included for relationship between β1 AR polymorphisms and susceptibility to HF [12–25], while 8 studies evaluated the impact of β1 AR polymorphisms on HF therapy response to β-blocker [16,26–32], and 10 studies provided information on association between prognosis and β1 AR polymorphisms [12,15,19,29,32–38]. The reasons why studies were excluded were shown in Figure 1.

**β1 AR Polymorphisms and Susceptibility to HF**

A total of 14 case-control studies [12–25] containing 2979 patients and 3336 controls provided data on the association between β1 AR polymorphisms and the susceptibility to HF (14 for Arg389Gly and 8 for Ser49Gly, as shown in Table 1). The causes of HF were various, including idiopathic dilated cardiomyopathy (IDCM), hypertension and ischemic cardiomyopathy. Controls were mainly healthy population, and matched for area and ethnicity. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in all the publications. Studies were conducted in various populations of racial descent: 7 studies for whites, 4 involved East Asians, 1 study for blacks, 1 involved Mexicans, and 1 study was mixed. The distribution of genotypes in the control group deviated from HWE in 2 studies for Ser49Gly [12,23], and then a sensitivity analysis was carried out excluding these studies to avoid possible genotyping errors and/or population stratification. The distribu-
Table 1. The characters of the 27 eligible studies.

| Authors                | Year | Region       | Ethnicity | Type of study | Sample size (case/control) | Main assessments | Parameter                                                                 |
|------------------------|------|--------------|-----------|---------------|----------------------------|------------------|---------------------------------------------------------------------------|
| Wang L et al [12]      | 2010 | China        | East Asian| case-control  | 430/468                    | Ser49Gly, Arg389Gly | risk of HF, mortality and combined endpoint in 2 years                 |
| Paczkowska A et al [13]| 2009 | Poland       | White     | case-control  | 97/105                     | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Woodwiissi AJ et al [14]| 2008| South African| Black     | case-control  | 403/429                    | Arg389Gly        | risk of HF                                                                |
| Biolo A et al [15]     | 2008 | Brazil       | mixed     | case-control  | 201/141                    | Ser49Gly, Arg389Gly | risk of HF, mortality in 39.8 months                                    |
| Yu WP et al [16]       | 2006 | China        | East Asian| case-control  | 105/100                    | Arg389Gly        | risk of HF, DHR, ΔLVEF, ΔLVEDd, ΔLVESd with 3 months β-blocker treatment |
| Nonen S et al [17]     | 2005 | Japan        | East Asian| case-control  | 91/119                     | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Covolo L et al [18]    | 2004 | Italy        | White     | case-control  | 256/230                    | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Magnusson Y et al [19] | 2005 | Sweden       | White     | case-control  | 375/492                    | Ser49Gly, Arg389Gly | risk of HF, mortality in 5 years                                        |
| Small KM et al [20]    | 2002 | America      | mixed     | case-control  | 159/189                    | Arg389Gly        | risk of HF                                                                |
| Iwai C et al [21]      | 2002 | Japan        | East Asian| case-control  | 163/157                    | Arg389Gly        | risk of HF                                                                |
| Forleo C et al [22]    | 2007 | Italy        | White     | case-control  | 189/378                    | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Tesson F et al [23]    | 1999 | France       | White     | case-control  | 426/395                    | Arg389Gly        | risk of HF                                                                |
| Fragoso JM et al [24]  | 2006 | Mexico       | Mexican   | case-control  | 47/93                      | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Podlowski S et al [25] | 2000 | Germany      | White     | case-control  | 37/40                      | Ser49Gly, Arg389Gly | risk of HF                                                                |
| Metra M et al [26]     | 2010 | Italy        | White     | prospective   | 183                        | Arg389Gly        | ΔHR, ΔLVEF, ΔLVEDd, ΔLVESd with 6 months β-blocker treatment              |
| Chen L et al [27]      | 2007 | Australia    | White     | prospective and retrospective | 135                          | Ser49Gly, Arg389Gly | ΔLVEF, ΔLVEDd, ΔLVESd with 1 year β-blocker treatment                    |
| Luo M et al [28]       | 2007 | China        | East Asian| prospective   | 156                        | Arg389Gly        | ΔLVEF, ΔLVESd with 3 months β-blocker treatment                           |
| Liggett SB et al [29]  | 2006 | America      | Mixed     | prospective   | 515                        | Arg389Gly        | ΔHR, ΔLVEF with β-blocker treatment, mortality in 12 months              |
| Terra SG et al [29]    | 2005 | America      | Mixed     | prospective   | 54                         | Ser49Gly, Arg389Gly | ΔHR, ΔLVEF, ΔLVEDd, ΔLVESd with 3 months β-blocker treatment              |
| de Groot P et al [31]  | 2005 | France       | White     | prospective   | 199                        | Ser49Gly, Arg389Gly | ΔHR, ΔLVEF with 3 months β-blocker treatment                             |
| Miallet Perez J et al [32]| 2003| America      | NS        | retrospective | 224                        | Arg389Gly        | ΔLVEF after 6 months β-blocker treatment                                 |
| Petersen M et al [32]  | 2011 | Denmark      | White     | retrospective | 305                        | Arg389Gly        | mortality in 6.7 years                                                   |
| Leineweber K et al [34]| 2010 | Germany      | White     | prospective   | 226                        | Ser49Gly, Arg389Gly | mortality in 45 months                                                  |
| Cresci S et al [35]    | 2009 | America      | Mixed     | prospective   | 1133                       | Arg389Gly        | mortality and combined endpoint in 6.5 years                             |
| White HL et al [36]    | 2003 | UK and Netherland | White | retrospective | 600                        | Arg389Gly        | combined endpoint in 12 months                                          |
| Forleo C et al [37]    | 2004 | Italy        | White     | prospective   | 171                        | Ser49Gly, Arg389Gly | combined endpoint in 33 months                                          |
| Shin J et al [38]      | 2007 | America      | Mixed     | prospective   | 227                        | Ser49Gly, Arg389Gly | mortality and combined endpoint in 2.8 years                             |

HF, heart failure; LVEF, left ventricular ejection fraction; LVEDd/v, left ventricular end diastolic diameter/volume; LVESd/v, left ventricular end systolic diameter/volume; combined endpoint, including death, heart transplantation and hospitalization; NS, not stated.

doi:10.1371/journal.pone.0037659.t001
tion of the β1 AR genotypes for cases and controls was shown in Table 2.

The results for the associations between the β1 AR polymorphisms and the risk of HF were shown in Table 3. In general population, the Arg389Gly polymorphism was not significantly associated with HF for all genetic models, the heterogeneity among studies was significant (Gly vs. Arg: \( P_h = 0.01, I^2 = 52\% \)). In subgroup analysis by ethnicity, in East Asians Gly389 allele increased the susceptibility to HF (RR = 1.10; 95% CI: 1.01–1.19, \( P = 0.03 \)), and Gly389 homozygote was significantly associated with a 35% increased risk of HF compared with Arg389 carrier (RR = 1.35; 95% CI: 1.16–1.57, \( P < 0.01 \)); in contrast, Gly389 allele (RR = 0.94; 95% CI: 0.89–1.00, \( P = 0.06 \)) and Gly389 homozygote (RR = 0.94; 95% CI: 0.71–1.00, \( P = 0.05 \)) trend to decrease the risk of HF in whites. Among blacks, there was not a significant relationship between the Arg389Gly polymorphism and HF.

For the Ser49Gly polymorphism, overall, the heterogeneity among studies was significant \( (P_h < 0.01, I^2 = 80\% ) \). The Gly49 allele significantly increased HF risk (RR = 1.22; 95% CI: 1.04–1.43, \( P = 0.02 \)) compared with Ser49, while Gly49 carrier had significantly higher risk of HF than Ser49Ser homozygote (RR = 1.33; 95% CI: 1.03–1.72, \( P = 0.03 \)). But neither of the associations was significant in sensitivity analysis. In ethnicity subgroup analysis, Gly49 significantly increased HF risk compared with Ser49 (RR = 1.18; 95% CI: 1.06–1.31, \( P < 0.01 \)) in East
Table 2. The distribution of the Arg389Gly and Ser49Gly genotype for cases and controls.

| Polymorphism | Arg389Arg (or Ser49Ser) | Arg389Gly (or Ser49Gly) | Gly389Gly (or Gly49Gly) | Arg389 (or Ser49) | Gly389 (or Gly49) | P HWE Controls |
|--------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-----------------|
|               | HF          | control | HF          | control | HF          | control | HF          | control | HF          | control | P HWE Controls |
| Wang L 2010   | Ser49Gly    | 270     | 338         | 152      | 130         | 8        | 0          | 692      | 806       | 168       | 130       | 0.00048       |
| Wang L 2010   | Arg389Gly   | 263     | 316         | 135      | 139         | 32       | 13         | 661      | 771       | 199       | 165       | 0.62323       |
| Paczkowska A 2009 | Ser49Gly | 76      | 87          | 21       | 17          | 0        | 1          | 173      | 191       | 21        | 19        | 0.86769       |
| Paczkowska A 2009 | Arg389Gly | 57      | 50          | 35       | 47          | 5        | 8          | 149      | 147       | 45        | 63        | 0.50042       |
| Woodiwiss AJ 2008 | Arg389Gly | 200     | 210         | 161      | 172         | 42       | 47         | 561      | 592       | 245       | 266       | 0.19305       |
| Biolo A 2008   | Ser49Gly    | 146     | 105         | 50       | 30          | 5        | 6          | 342      | 240       | 60        | 42        | 0.05634       |
| Biolo A 2008   | Arg389Gly   | 112     | 81          | 72       | 52          | 17       | 8          | 296      | 214       | 106       | 68        | 0.92718       |
| Yu WP 2006     | Arg389Gly   | 54      | 53          | 42       | 40          | 9        | 7          | 150      | 146       | 60        | 54        | 0.88303       |
| Nonen S 2005   | Ser49Gly    | 66      | 83          | 21       | 33          | 4        | 3          | 153      | 199       | 29        | 39        | 0.896        |
| Nonen S 2005   | Arg389Gly   | 60      | 79          | 26       | 35          | 5        | 5          | 146      | 193       | 36        | 45        | 0.65567       |
| Covolo L 2004  | Arg389Gly   | 119     | 122         | 116      | 90          | 21       | 18         | 354      | 334       | 158       | 126       | 0.8053       |
| Magnusson Y 2005 | Ser49Gly | 255     | 333         | 110      | 148         | 10       | 11         | 620      | 814       | 130       | 170       | 0.24506       |
| Magnusson Y 2005 | Arg389Gly | 218     | 266         | 140      | 201         | 15       | 25         | 576      | 733       | 170       | 251       | 0.09614       |
| Small KM 2002 (blacks) | Arg389Gly | 43      | 63          | 34       | 34          | 4        | 8          | 120      | 160       | 42        | 50        | 0.27066       |
| Small KM 2002 (whites) | Arg389Gly | 23      | 23          | 36       | 48          | 19       | 13         | 82       | 94        | 74        | 74        | 0.14432       |
| Forleo C 2007  | Ser49Gly    | 137     | 318         | 51       | 58          | 1        | 2          | 325      | 694       | 53        | 62        | 0.711        |
| Forleo C 2007  | Arg389Gly   | 100     | 173         | 78       | 159         | 11       | 46         | 278      | 505       | 100       | 251       | 0.31498       |
| Tesson F 1999  | Arg389Gly   | 261     | 231         | 140      | 136         | 25       | 28         | 662      | 598       | 190       | 192       | 0.20168       |
| Fragoso JM 2006 | Ser49Gly | 25      | 61          | 19       | 28          | 3        | 4          | 69       | 150       | 25        | 36        | 0.73168       |
| Fragoso JM 2006 | Arg389Gly | 24      | 69          | 20       | 20          | 3        | 4          | 68       | 158       | 26        | 28        | 0.12488       |
| Iwai C 2002    | Arg389Gly   | 88      | 74          | 54       | 71          | 21       | 12         | 230      | 219       | 96        | 95        | 0.36985       |
| Podlowski S 2000 | Ser49Gly | 31      | 40          | 5        | 0           | 1        | 0          | 67       | 80        | 7         | 0         | –             |
| Podlowski S 2000 | Arg389Gly | 19      | 21          | 16       | 18          | 2        | 1          | 54       | 60        | 20        | 20        | 0.2059        |

HWE: Hardy-Weinberg Equilibrium.
doi:10.1371/journal.pone.0037659.t002
Asians, however, it was not robust either. No association between the risk of HF and Ser49Gly polymorphism was found in whites.

**β1 AR Polymorphisms and Response to β-blocker Therapy**

Eight studies [16,26–32] evaluated the impact of β1 AR polymorphisms on response to β-blocker therapy: 2 involved East Asians, 3 studies for whites, and 3 studies were mixed (Americans, mainly composed of blacks and Caucasians). ΔHR and parameters of LV remodeling (ΔLVEF, ΔLVEDd/v, and ΔLVESd/v) were used to assess the response to β-blocker therapy with at least 3 months follow up. All the 1561 patients with a LVEF ≤45% received concomitant drug therapy, which included β-blocker, angiotensin converting-enzyme (ACE) inhibitor (or an angiotensin receptor blocker if the ACE inhibitor was not tolerated), spironolactone, digoxin, diuretics and so on. The kinds of β-blockers were various, comprised selective β1-blockers (metoprolol, bisoprolol) and non-selective β-blockers (carvedilol, bucindolol). And the dose of β-blockers was the target dose according to guideline or a maximum tolerated dose. The LVEF, LVEDd/v and LVESd/v were measured with echocardiogram or radionuclide ventriculography.

Five studies [16,26,29–31] including 1056 patients provide information on the reduction of heart rate after β-blocker therapy. There was not a significant difference in the reduction of heart rate between Arg389 homozygotes and Gly389 carriers (WMD = −0.47, 95% CI: −1.65–0.71, P = 0.43, Figure 2A). Even in different ethnicities, the HR reductions with β-blockers treatment were comparable in the Arg389 homozygotes and Gly389 carriers. Compared with Gly389 carriers, overall, there was a significant improvement in LV remodeling in Arg389 homozygotes. Eight studies [16,26–32] containing 1602 patients indicated that the improvement of LVEF was better in Arg389 homozygotes (WMD = 1.83, 95% CI: 0.72–2.94, P < 0.01, Figure 2B). And another meta-analysis including 4 studies [16,26,27,29] and 477 patients showed that the LVEDd/v improvement of Arg389 homozygotes trended to be better than Gly389 carriers (SMD = −0.16, 95% CI = −0.35–0.02, P = 0.07, Figure 2C).

### Table 3. RRs and Heterogeneity Results for the Genetic Contrasts of Arg389Gly and Ser49Gly β1 AR Polymorphisms for HF.

| Polymorphism          | Ethnicity | RR (95% CI) | Studies | I², % | P_h | Overall effect, P |
|-----------------------|-----------|-------------|---------|-------|-----|------------------|
| Arg389Gly             | All       | 1.01 (0.95, 1.08) | 14      | 52    | 0.01 | 0.66             |
|                       | Asian     | 1.10 (1.01, 1.19)  | 4       | 26    | 0.25 | 0.03             |
|                       | White     | 0.94 (0.89, 1.00)  | 7       | 38    | 0.14 | 0.06             |
|                       | Black     | 1.00 (0.91, 1.10)  | 2       | 0     | 0.5  | 0.98             |
| Gly389 carrier vs. Arg389Arg | All       | 1.00 (0.93, 1.08)  | 14      | 41    | 0.05 | 0.98             |
|                       | Asian     | 1.05 (0.95, 1.17)  | 4       | 35    | 0.2  | 0.31             |
|                       | White     | 0.95 (0.88, 1.03)  | 7       | 34    | 0.17 | 0.19             |
|                       | Black     | 0.98 (0.86, 1.12)  | 2       | 0     | 0.84 | 0.77             |
| Gly389Gly vs. Arg389 carrier | All       | 1.08 (0.93, 1.24)  | 14      | 50    | 0.01 | 0.31             |
|                       | Asian     | 1.35 (1.16, 1.57)  | 4       | 0     | 0.48 | 0.0001           |
|                       | White     | 0.84 (0.71, 1.00)  | 7       | 0     | 0.46 | 0.05             |
|                       | Black     | 1.05 (0.87, 1.27)  | 2       | 50    | 0.16 | 0.62             |
| Ser49Gly              | All       | 1.22 (1.04, 1.43)  | 8       | 80    | <0.01| 0.02             |
|                       | Sensitivity| 1.11 (0.97, 1.27)  | 6       | 51    | 0.07 | 0.13             |
|                       | Asian     | 1.18 (1.06, 1.31)  | 2       | 44    | 0.18 | 0.003            |
|                       | White     | 1.34 (0.95, 1.90)  | 4       | 90    | <0.01| 0.1              |
| Gly49 carrier vs. Ser49Ser | All       | 1.33 (1.03, 1.72)  | 8       | 52    | 0.04 | 0.03             |
|                       | Sensitivity| 1.25 (0.94, 1.66)  | 6       | 48    | 0.08 | 0.12             |
|                       | Asian     | 1.24 (0.72, 2.13)  | 2       | 64    | 0.09 | 0.44             |
|                       | White     | 1.48 (0.86, 2.57)  | 4       | 72    | 0.01 | 0.16             |
| Gly49Gly vs. Ser49 carrier | All       | 1.24 (0.74, 2.08)  | 8       | 81    | <0.01| 0.42             |
|                       | Sensitivity| 1.03 (0.76, 1.39)  | 6       | 0     | 0.84 | 0.86             |
|                       | Asian     | 1.72 (0.95, 3.12)  | 2       | 69    | 0.07 | 0.07             |
|                       | White     | 1.08 (0.73, 1.62)  | 4       | 0     | 0.76 | 0.69             |

doi:10.1371/journal.pone.0037659.t003
and also a trend of better improvement of LVEDd/v (SMD = -0.19, 95% CI = -0.41–0.03, P = 0.09, Figure 2C).

In another subgroup analysis, the LVEF improvement of Arg389 homozygotes was significantly greater than Gly389 carriers (SMD = 2.08, 95% CI: 0.94–3.22, \( P \leq 0.01 \), Figure 3) in patients treated with selective \( \beta_1 \)-blockers, but non-selective \( \beta \)-blockers did not achieve different LVEF improvements between Arg389 homozygotes and Gly389 carriers (SMD = 1.90, 95% CI: 0.46–4.26, \( P = 0.11 \), Figure 3).

**Sensitivity Analysis**

The small sample studies (sample size <100) [25,29] involved in our meta-analysis were deleted to reflect the influence of them on our data and conclusion. And the pooled RRs were not significantly altered, indicating that the results were robust.

**Publication Bias**

Begg’s funnel plots were performed to access the publication bias of susceptibility to HF, response to \( \beta \)-blocker therapy and prognosis of HF. The funnel plots appeared symmetric, suggesting the absence of publication bias (data not shown).

**ADRB1 Polymorphisms and Prognosis of HF**

A total of 10 studies evaluated the impact of \( \beta_1 \) AR polymorphisms on HF mortality and/or combined endpoint incidence. In 2 of them, the kind of \( \beta \)-blocker was fixed (BEST research: bucindolol, MERIT-HF: metoprolol CR/XL). Patients in the other 8 studies were mostly treated with \( \beta \)-blockers (at least 70%), and the kinds and dose of \( \beta \)-blockers (metoprolol, bisoprolol, carvedilol and other \( \beta \)-blocker) were decided by the subjects’ physicians. The patients were mostly whites in the 10 studies, in which the causes of HF were various (ischemic/IDCM/hypertension).

There was no significant difference between Arg389 homozygotes and Gly389 carriers in all-cause mortality (RR = 1.07; 95% CI: 0.94–1.21, \( P = 0.29 \), Figure 4A) or combined endpoint (RR = 1.05; 95% CI: 0.95–1.16, \( P = 0.37 \), Figure 4B). And all-cause mortality of Ser49 homozygotes was not significantly different with Gly49 carriers (RR = 1.36; 95% CI: 0.93–2.01, \( P = 0.12 \), Figure 4C), so it was with the combined end-point (RR = 0.94; 95% CI: 0.61–1.44, \( P = 0.76 \), Figure 4D).
Discussion

The purpose of diagnosing and treating HF is bringing about a reduction of mortality and morbidity. Preventive measurements can be undertaken early according to the risk factor for the development of HF, while appropriate therapeutic decision would be made by accurate prediction of response to β-blockers. Therefore, predictors of susceptibility to HF and response to β-blockers treatment are needed in clinical practice. Sustained sympathetic system activation has been shown to be deleterious to the failing heart, and the transmitters of this system, adrenaline and noradrenaline act on β-receptors situated on cardiomyocytes,
which are mostly of the β1-subtype [8]. The β-blockers recommended by the guidelines – metoprolol, bisoprolol, carvedilol can block β1-receptors as their common function [1,2]. Therefore, the β1 adrenergic receptor plays decisive role in the development and treatment of HF. In vitro and in vivo experiments showed that agonist-related downregulation in Gly49 variant was significantly greater than Ser49 [39]. It was also found that Arg389 receptor would have a greater agonist-promoted coupling to Gs/adenyl cyclase compared with Gly389 [40], and β1-AR Arg389 desensitized more rapidly than the Gly389 variant [41]. Since the important role of β1 AR in HF, it was inferred that the two functional polymorphisms would predict the susceptibility to HF, the response to β-blockers treatment, and even the prognosis of HF. However, there was no large scale study to verify the relationship.

We have performed a meta-analysis on the impact of β1 adrenergic receptor polymorphisms on susceptibility to heart failure, response to β-blocker therapy and HF prognosis, including data on over 7000 patients and 3000 healthy controls. It has been found that Gly389 allele and Gly389 homozygote increased the risk of HF in East Asians, but tended to decrease the risk of HF in whites. Overall the response to β-blockers in Arg389 homozygote was greater than that in Gly389 carrier while the reductions of HR were similar. But the Arg389 homozygotes did not confer a significant prognosis benefit in heart failure patients. The Ser49Gly polymorphism was associated with neither risk nor prognosis of HF.

There was evidence in transgenic mice to show that Arg389 allele was a risk factor of HF [42], while there may be a role for the Ser49Gly polymorphism in the susceptibility to HF [43]. In the present meta-analysis, Gly49 allele increased the HF risk in the general population and in East Asians, but the result was not robust in sensitivity analysis. In the studies with the controls not in HWE, the lack of HWE indicates genotyping errors, population stratification, and selection bias, which could be potential sources of biases [9]. Recently, a meta-analysis [44] found that the Gly389Gly significantly increased risk of idiopathic dilated cardiomyopathy (IDCM) in Asians, which consisted with our result. But in that study, Arg389Gly was not associated with susceptibility to IDCM in Europeans. In our study, the causes of HF included IDCM, hypertension and ischemic cardiomyopathy. The important role of Arg389Gly in essential hypertension [45] and LV remodeling in patients following acute myocardial infarction (AMI) [46] could explain that Arg389Gly polymorphism affected the risk of HF but did not associate with susceptibility to IDCM in whites.

Furthermore, as a complex pathophysiological process, heart failure was involved in multi-genetic effect, thus other functional genes that affected the susceptibility to HF may mask the influence of β1 adrenergic receptor polymorphisms in different ethnics. In addition, environmental interactions (e.g., smoking, physical activity, and diet) may also play a role in the pathogenesis of HF [47]. In the future, the polymorphisms within haplotypes combined with environmental interactions can be a risk stratification tool of HF rather than the individual polymorphism.

Experiments in mice and healthy volunteers showed that the reduction of HR to β-blocker in Arg389 homozygotes was greater than that in Gly389 carriers [43,48]. However, in our meta-analysis the reductions of HR were comparable, which might be related with the downregulation of myocardial β1 AR in HF patients. While the improvements of LVEF and LVEDd/v were significantly better in Arg389 homozygotes, which also performed a trend for greater reduction of LVEDd/v. In clinic practice, doctors treat the patient would titrate β-blockers to achieve appropriate heart rate reduction. According to the results, Arg389Gly polymorphism may be a predictor of response to β-blocker treatment in HF patients, which is independent of HR. These findings would be useful in making individualized therapeutic decision in the future.

In another subgroup analysis, the Arg389 homozygotes performed a greater LVEF improvement to selective β1-blockers therapy than Gly389 carriers, but no differences were conferred by genotypes in the patients treated with non-selective β-blockers, as non-selective β-blockers also block β2 and β1 AR. The LVEF is an important indicator of response to treatment. Blockade of the β1AR is certainly responsible for a large degree of the improvement seen in HF, such as LVEF improvement and survival benefits, but it is not the sole mechanism. Previous studies have suggested that the release of norepinephrine is partly regulated by prejunctional β2-adrenergic receptors [49], and that β1-ARs can also increase contractility equal to β2-ARs in failing hearts [50]. As the importance of β2 and β1 AR in failing hearts, the role of β1 AR in patients who were treated with non-selective beta-blockers was weakened. Thus the association between the improvement of LVEF and Arg389Gly polymorphism was not significant among patients treated with non-selective β-blockers.

As the progression of heart failure is associated with LVEF, it is expected the Arg389 homozygotes would get a better efficacy by selective β1-blockers therapy and Gly389 carriers might benefit more from non-selective β-blockers, which needs further investigation.

In a study of 54 patients with HF, individuals with the Gly49 variant had greater improvement in LVEDd [29]. However, no association between Ser49Gly polymorphism and the change of LVEF was found [27,31]. The being few studies, these findings need to be further confirmed.

Although the therapeutic response to β-blockers was influenced by the β1 AR polymorphisms, no differences were found in the prognosis of heart failure. In theory, a better beta-blocker response might lead to potential adverse outcomes, such as HF deterioration, hypotension and bradycardia. But by now, there has been no data supporting the association between the β1 genetic polymorphisms and the adverse outcomes in prognosis. It is also believed that in the failing heart the density of β1 AR, especially the β1 AR, kept decreasing [51]. In our meta-analysis, the follow-up time of studies on prognosis of HF was relatively longer than that of studies on β-blocker responses. Thus the density of β1-AR in studies on prognosis of HF was more decreased than that in studies on beta-blocker responses. Therefore, the β1 AR played a more important role in response to β-blockers than that in prognosis of HF. Recently, a meta-analysis [32] has shown that the patients enrolled in the United States were associated with a lower magnitude of survival benefit to β-blockade than the ones from the rest of the world. The result demonstrated that the determining prognosis in HF is complex. Besides genetic factors, the cultural or social differences in disease management may also cover the impact of β1-AR polymorphisms. In addition, the sample size would have been too small to detect the differences.

In the future, large sample clinical trials which investigate both the response to beta-blockers and prognosis in the same group of patients may make more sense for this problem.

**Limitation**

First of all, we evaluated the relationships between heart failure and the two functional β1 AR polymorphisms, Ser49Gly and Arg389Gly respectively. Since the two polymorphisms are in strong linkage disequilibrium (LD) [53], the combined effects in
haplotypes may be more decisive in susceptibility to HF, response to β-blocker therapy, and prognosis.

Secondly, in the 10 studies for prognosis of HF, the percentage of patients treated with beta-blockers ranged from 70% to 100%. The non-treated cases could not be excluded so that our results would inevitably be compromised. It’s a limitation of our meta-analysis. But in reality, some patients with heart failure due to the presence of contraindications cannot use β-blockers. Therefore, we believe that the current results were closer to clinical practice.

At last, the sample size for each study was relatively small, even though all the studies in which the data could be achieved were collected for analysis, yet prospective studies with large sample size are warranted.

Conclusion

Based on the present meta-analysis, we found that the Gly389 allele and Gly389 homozygote were associated with the increasing risk of HF in East Asians; but in whites, Gly389 allele and Gly389 homozygote tended to decrease the risk of HF. The Ser49Gly polymorphism of β1 receptor was not associated with risk of HF. With the similar reduction of heart rate, overall, the Arg389 homozygotes performed a better response to β-blocker therapy. Furthermore, the Arg389 homozygotes were significantly associated with better LVEF improvement in East Asians and mixed population. And in white people, the Arg389 homozygotes made a greater LVESe/d/v improvement and trended to be associated with better LVEDd/v improvement. However, neither of the two β1 AR polymorphisms impacted the prognosis of HF based on our data. The results of our meta-analysis would provide a reference for individualized treatment of HF, and are also helpful in future prospective clinical trials.

Supporting Information

Checklist S1.

Acknowledgments

We thank everyone who helped with this study.

Author Contributions

Conceived and designed the experiments: W-NL Z-HW. Performed the experiments: W-NL K-LF. Analyzed the data: W-NL Y-YS Z-HW. Contributed reagents/materials/analysis tools: W-NL K-LF G-HJ. Wrote the paper: W-NL H-YG. Critical revision of the manuscript for important intellectual content: YZ WZ MZ.

References

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2006) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933–989.

2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1–e90.

3. Fang J, Mensah GA, Groff JB, Keanen NK (2008). Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52: 429–434.

4. de Groote P, Delour P, Mouquet F, Lamblin N, Dagorn J, et al. (2007) The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J 154: 589–95.

5. Seghalot FF, Shah DJ, Dhiuhot S, Bello D, Johnson MR, et al. (2004) Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 154: 589–95.

6. Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145: 200–202.

7. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, et al. (2003) Marked improvement in left ventricular ejection fraction during long term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 145: 292–299.

8. Lehie MJ (2004) Beta-adrenoceptor polymorphisms and heart failure. Trends Mol Med 10: 55–58.

9. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons. 672 p.

10. Weir BS. (1990) Genetic Data Analysis: Methods for Discrete Population Genetic Data. Sinauer Associates. 377 p.

11. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.

12. Wang L, Lu L, Zhang F, Chen Q, Shen W (2010) Polymorphisms of beta-adrenoceptor and natriuretic peptide receptor genes influence the susceptibility to and the severity of idiopathic dilated cardiomyopathy in a Chinese cohort. J Card Fail 16: 36–44.

13. Paczkowska A, Szerpl M, Malek L, Mazurkiewicz I, Skóra E, et al. (2009) Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol 67: 235–241.

14. Woodiwiss AJ, Baderstedt D, Sinicro K, Broosbank R, Esopw R, et al. (2008) Beta1- and alpha2-adrenoceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry. Cardiovasc J Afr 19: 188–193.

15. Bido A, Clauvel N, Santos KG, Salvaro R, Ashton-Prolla P, et al. (2008) Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 102: 726–732.

16. Yu WP, Lou M, Deng B, Song HM, Wang HB (2006) Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 34: 776–780.

17. Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y (2005) No positive association between adrenergic receptor variants of alpha2-AD322 to 325, betaSer49, and beta3Arg89 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 63: 414–417.

18. Covolo L, Gelatti U, Metra M, Nodari S, Picciché A, et al. (2004) Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J 25: 1334–1341.

19. Magnusson Y, Levin MC, Egnersson R, Nyström E, Mohlini R, et al. (2005) Ser9Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78: 221–231.

20. Sonal KM, Wagener LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135–1142.

21. Iwai C, Akita H, Shiga N, Takai E, Miyamoto Y, et al. (2002) Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 66: 723–728.

22. Forleo C, Sorrentino S, Guida P, Romiti R, De Tommasi E, et al. (2007) Beta1- and beta2-adrenoceptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 8: 589–590.

23. Tesson F, Charron P, Puchmaur M, Nicaud V, Cambien F, et al. (1999) Characterization of a unique genetic variant in the beta1-adrenergic gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 31: 1025–1032.

24. Fragoso JM, Rodríguez-Pérez JM, González-J, Cruz D, Pérez-Mñdez O, et al. (2006) Beta1-adrenergic receptor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 80: 279–282.

25. Podolski S, Wenzel K, Luther HP, Müller J, Beanlage P, et al. (2000) Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Cell Cardiol 27: 833–839.

26. Fumero A, Paglia I, Lugetti SB, Mainelli-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif

PloS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e37659

ADRB1 Polymorphisms and HF: A Meta-Analysis
1. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, et al. (2001) Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104: 2194–2199.

2. Djousse´L, O’Connell TD, Simpson PC (2010) Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51: 518–528.

3. Brodde OE (1991) Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.

4. O’Connor CM, Fuziat M, Swedberg K, Caron M, Koch B, et al. (2011) Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol 58: 913–922.

5. Muthumala A, Drenos F, Elliott PM, Humphries SE (2008) Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 10: 3–13.